The global cardiac biomarkers market size was valued at USD 18.62 billion in 2024. The market is projected to grow from USD 20.90 billion in 2025 to USD 47.43 billion by 2032, exhibiting a CAGR of 12.4% during the forecast period. North America dominated the cardiac biomarkers market with a market share of 39.09% in 2024.

The cardiac biomarkers market is experiencing robust growth, driven by the rising global burden of cardiovascular diseases and an increasing emphasis on early and accurate diagnosis. These biomarkers play a critical role in detecting heart conditions such as myocardial infarction, heart failure, and acute coronary syndrome, enabling timely treatment decisions. The market is benefiting from technological advancements in diagnostic tools, the expansion of point-of-care testing, and growing healthcare awareness among patients. Additionally, favorable government initiatives and increased healthcare spending are supporting the adoption of cardiac biomarker testing. As demand continues to rise across both developed and emerging regions, the cardiac biomarkers market is poised for significant expansion in the coming years.

Continue reading for more details:

**https://www.fortunebusinessinsights.com/industry-reports/cardiac-biomarkers-market-101233**

Market Segmentation

By Biomarker Type

• Troponin
• Creatine Kinase-MB (CK-MB)
• B-type Natriuretic Peptide (BNP) and N-terminal pro-BNP (NT-proBNP)
• Myoglobin
• High-sensitivity C-reactive protein (hs-CRP)
• Others

By Application

• Acute Coronary Syndrome
• Myocardial Infarction
• Congestive Heart Failure
• Atherosclerosis
• Others

By Testing Location